PDF-Ledipasvir Sofosbuvir in GT and HIV Coinfection NIAID

JAMA 20153131232 9 HIV Coinfection brPage 2br Source Osinusi A et al JAMA 20153131232 9 Ledipasvir Sofosbuvir in GT1 with HIV Coinfection NIAID ERADICATE Trial Features NIAID ERADICATE Trial Design Open label phase 2 using fixed dose combination o. Open-label. W12. ≥ 18 years. Chronic HCV infection. Genotype . 1. Treatment naïve. HIV infection on stable ART ≥ 8 weeks and HIV RNA < 50 c/ml and CD4 ≥ 100/mm. 3. o. r no ART and CD4 ≥ 500/mm. NIH SPARE. Phase . 2. Treatment. . Naïve . (unfavorable baseline treatment . characteristics). Osinusi. A, et al. JAMA. 2013;310:804-11.. Source: . Osinusi. A,. . et al. . JAMA. 2013;310:804-11.. . or 3 . LONESTAR-2. Phase 2. Treatment. . Experienced. Lawitz. . E, et al. . Hepatology. . 2015:61:769-75.. Source: . Lawitz. E, et al. . Hepatology. . . 2015:61:769-75.. Sofosbuvir + . PEG + RBV . ASTRAL-1. Phase 3. . Treatment. . Naïve & Experienced. Feld JJ, . et al. . N . Engl. J Med. . 2015. ;373:2599-607.. Source: Feld . JJ. , et al. N . Engl. J Med. . 2015. ;373:2599-607.. Sofosbuvir-Velpatasvir. SOLAR-1 (Cohorts A and B). Phase . 2 . Treatment Naïve and Treatment Experienced. Charlton M, al. Gastroenterology. 2015; 149:649-59.. Source: Charlton M, . et al. . Gastroenterology. 2015; 149:649-59.. ). Slide deck prepared . by: . David H. Spach, MD and H. Nina Kim, MD MSc. Last . Updated: . October 23, . 2014. Robe. rt G. Gish MD. Professor, Consultant, Stanford University Medical Center. Senior Medical Director, St Josephs Hospital and Medical Center, Liver Program, Phoenix, Arizona. Presented by: . Fabian Cretu, Beverly-Ann Oliver, Kristina Miclat, Maeryl Sumagang. PHM142. September 25, 2018. PHM142 Fall . 2018. Instructor: . Ms. Maya Latif. Coordinator: Dr. J. Henderson. HIV. . Case. 47-Year-Old . Man With Asymptomatic HIV Infection. Case (cont). Initial Clinical Presentation. Laboratory Results. HepaScore. ®. A Composite Biomarker Panel for Liver Fibrosis. Hepatic Steatosis in Patients With HIV/HCV Coinfection. Update. David Spach, MD. Professor of Medicine, Division of Infectious Diseases. University of Washington. Last Updated: . June 12. , 2013. Chronic Viral Diseases and Mortality in United States. Which one of the chronic viral diseases was responsible for the most number of deaths in the United States in 2007?. University of Chicago. Chicago, Illinois. Challenges in the Management and Treatment of HIV/Hepatitis C Virus Coinfection. FORMATTED: 05/02/2016. Chicago, Illinois: May 9, 2016. From . AI . Aronsohn. POC/Title and or Institute/Website. : Natalia Kruchinin . Ph.D., . NIAID,NIH SBIR/STTR . Program . Coordinator email: . kruchininn@niaid.nih.gov. http. ://. www.niaid.nih.gov/researchfunding/sb/Pages/default.aspx. Programmatic Interests. 1. National . Institute. . of Allergy and Infectious Diseases (NIAID. ), NIH. Mike Minnicozzi, Ph.D.. Program Officer-DAIT. 2. Division . of Intramural Research (DIR) . Division of Clinical Research (DCR) . FIM4R Meeting 17FEB2020. @TIIME. Vienna, Austria. This presentation. Progress . On-Prem Service Providers. Off-Prem/Commercial SaaS Service Providers. Challenges . science is scientists. Next Steps. OIDC. SOLAR-2. Source: . Manns. M, et al. Lancet Infect Dis. 2016;16:685-97.. Treatment Naïve and Treatment Experienced, Phase 2. Ledipasvir-Sofosbuvir + Ribavirin in Advanced Liver Disease. SOLAR-2: Features.